Please use this identifier to cite or link to this item:
Title: Responsive exosome nano-bioconjugates for synergistic cancer therapy
Authors: Nie, Weidong
Wu, Guanghao
Zhang, Jinfeng
Huang, Li-Li
Ding, Jingjing
Jiang, Anqi
Zhang, Yahui
Liu, Yanhong
Li, Jingchao
Pu, Kanyi
Xie, Hai-Yan
Keywords: Engineering::Chemical engineering
Issue Date: 2020
Source: Nie, W., Wu, G., Zhang, J., Huang, L., Ding, J., Jiang, A., Zhang, Y., Liu, Y., Li, J., Pu, K. & Xie, H. (2020). Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angewandte Chemie International Edition, 59(5), 2018-2022.
Journal: Angewandte Chemie International Edition
Abstract: Exosomes hold great potential in therapeutic development. However, native exosomes usually induce insufficient effects in vivo and simply act as drug delivery vehicles. Herein, we synthesize responsive exosome nano-bioconjugates for cancer therapy. Azide-modified exosomes derived from M1 macrophages are conjugated with dibenzocyclooctyne-modified antibodies of CD47 and SIRPα (aCD47 and aSIRPα) through pH-sensitive linkers. After systemic administration, the nano-bioconjugates can actively target tumors through the specific recognition between aCD47 and CD47 on the tumor cell surface. In the acidic tumor microenvironment, the benzoic-imine bonds of the nano-bioconjugates are cleaved to release aSIRPα and aCD47 that can, respectively, block SIRPα on macrophages and CD47, leading to abolished "don't eat me" signaling and improved phagocytosis of macrophages. Meanwhile, the native M1 exosomes effectively reprogram the macrophages from pro-tumoral M2 to anti-tumoral M1.
ISSN: 1433-7851
DOI: 10.1002/anie.201912524
Rights: © 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SCBE Journal Articles

Citations 5

Updated on Nov 29, 2022

Web of ScienceTM
Citations 5

Updated on Nov 27, 2022

Page view(s)

Updated on Dec 3, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.